selegiline has been researched along with Parkinsonian Disorders in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 17 (62.96) | 29.6817 |
| 2010's | 7 (25.93) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, K; Jin, M; Li, L; Liu, D; Luo, N; Rong, H; Wang, J; Zhang, J; Zhang, X; Zhang, Y | 1 |
| Arawaka, S; Kato, T; Nakamura, Y; Sasaki, A; Sato, H; Shigekiyo, T; Takahata, K; Tsunekawa, H | 1 |
| Chen, NH; Heng, Y; Huang, JY; Mou, Z; Yuan, YH; Zhang, QS | 1 |
| Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H | 1 |
| Carlsson, T; Chiu, WH; Depboylu, C; Höglinger, GU; Oertel, WH; Ries, V | 1 |
| Correa, M; Dortche, K; Podurgiel, SJ; Salamone, JD; Yohn, SE | 1 |
| Canning, SD; Wang, XP; Zhang, LL | 1 |
| Chan, KY; Fung, CW; Hui, J; Ko, CH; Lam, CW; Low, L; Mak, CM; Siu, S; Wong, VC; Yau, E; Yeung, WL | 1 |
| Choudhury, ME; Kubo, M; Matsuda, S; Moritoyo, T; Nagai, M; Nishikawa, N; Nomoto, M; Yabe, H | 1 |
| Fujimaru, S; Matsubara, K; Ohtaki, K; Saito, O; Shimizu, K; Shiono, H | 1 |
| Mohanakumar, KP; Muralikrishnan, D; Samantaray, S | 1 |
| Iida, Y; Ogawa, M; Saji, H; Shimazu, S; Takahata, K; Yoneda, F | 1 |
| Iida, Y; Saji, H; Shimazu, S; Takahata, K; Tamashiro, A; Yoneda, F | 1 |
| Bader, V; Foguet, M; Lübbert, H; Schoenebeck, B; Siebertz, B; Stichel, CC; Zhu, XR | 1 |
| Bhat, V; Weiner, WJ | 1 |
| Mohanakumar, KP; Saravanan, KS; Senthilkumar, KS; Sindhu, KM | 1 |
| Brackenborough, KT; Chapman, H; Pangalos, MN; Perren, MJ; Quinn, LP; Upton, N; Vidgeon-Hart, M; Virley, DJ; Woodhams, PL | 1 |
| Ando, K; Higuchi, M; Inaji, M; Maeda, J; Obayashi, S; Okauchi, T; Suhara, T; Tanioka, Y | 1 |
| Elizur, A; Levin, J; Rabey, JM; Rapoport, A; Schwartz, M; Stein, D; Stier, S | 1 |
| Brusa, L; Gasparini, M; Meco, G; Vanacore, N | 1 |
| Hengerer, B; Spooren, WP; Waldmeier, PC | 1 |
| Gerlach, M; Riederer, P; Sian, J | 1 |
| Casas, M; Pérez, V; Prat, G; Rubi, A; Unzeta, M | 1 |
| Morón, J; Pastó, M; Pérez, V; Unzeta, M | 1 |
| Castagnoli, K; Castagnoli, N; Steyn, S; Steyn, SJ | 1 |
| Castagnoli, K; Castagnoli, N; Steyn, SJ | 1 |
| Breithaupt, W; Gerlach, M; Götz, ME; Kupsch, A; Oertel, WH; Riederer, P; Sautter, J; Schwarz, J; Youdim, MB | 1 |
3 review(s) available for selegiline and Parkinsonian Disorders
| Article | Year |
|---|---|
Freezing of Gait in Parkinsonism and its Potential Drug Treatment.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Botulinum Toxins; Droxidopa; Gait Disorders, Neurologic; Humans; Indans; Levodopa; Methylphenidate; Middle Aged; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Selegiline; Treatment Outcome | 2016 |
Parkinson's disease. Diagnosis and the initiation of therapy.
Topics: Antioxidants; Diagnosis, Differential; Dopamine Agonists; Humans; Hypokinesia; Indans; Levodopa; Muscle Rigidity; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Selegiline; Tremor | 2005 |
Is there neuroprotection in Parkinson syndrome?
Topics: Dopamine Agonists; Drug Therapy, Combination; Humans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinsonian Disorders; Receptors, N-Methyl-D-Aspartate; Selegiline; Vitamin E | 2000 |
1 trial(s) available for selegiline and Parkinsonian Disorders
| Article | Year |
|---|---|
A trial of L-deprenyl for the treatment of neuroleptic-induced parkinsonism.
Topics: Adult; Analysis of Variance; Antiparkinson Agents; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Psychiatric Status Rating Scales; Regression Analysis; Schizophrenia; Selegiline | 1999 |
23 other study(ies) available for selegiline and Parkinsonian Disorders
| Article | Year |
|---|---|
Neuroprotective effect of paeoniflorin in the mouse model of Parkinson's disease through α-synuclein/protein kinase C δ subtype signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Annexin A5; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Apoptosis; Disease Models, Animal; Glucosides; Mice; Microscopy, Electron, Transmission; Monoterpenes; Neurotoxins; Parkinsonian Disorders; Protein Kinase C-delta; Rotarod Performance Test; Selegiline; Substantia Nigra | 2021 |
Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
Topics: alpha-Synuclein; Animals; ATP-Binding Cassette Transporters; Cell Death; Cell Line, Tumor; Corpus Striatum; Culture Media, Conditioned; Dopaminergic Neurons; Gene Knockdown Techniques; Genetic Vectors; Humans; Indans; Injections; Lysosomes; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Mutation, Missense; Neuroblastoma; Parkinsonian Disorders; Protein Aggregation, Pathological; Protein Transport; Rats; Rats, Sprague-Dawley; Recombinant Proteins; RNA, Small Interfering; Selegiline; Substantia Nigra | 2021 |
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Benzothiazoles; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Drug Combinations; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Parkinsonian Disorders; Pramipexole; Selegiline | 2017 |
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Movement; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Time Factors | 2018 |
Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell Count; Cell Survival; Dopamine Agents; Dopaminergic Neurons; Hippocampus; Levodopa; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Neural Stem Cells; Neurogenesis; Neuroprotective Agents; Olfactory Bulb; Oxidopamine; Parkinsonian Disorders; Selegiline | 2014 |
The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Jaw; Male; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Random Allocation; Rats, Sprague-Dawley; Selegiline; Tetrabenazine; Tremor; Vesicular Monoamine Transport Proteins | 2016 |
Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency.
Topics: Adolescent; Adult; Child; Child, Preschool; Deficiency Diseases; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinsonian Disorders; Phenotype; Prolactin; Selegiline; Severity of Illness Index; Treatment Outcome; Tyrosine 3-Monooxygenase | 2011 |
Zonisamide attenuates MPTP neurotoxicity in marmosets.
Topics: Animals; Antiparkinson Agents; Callithrix; Corpus Striatum; Dopamine; Female; Humans; Isoxazoles; Male; MPTP Poisoning; Neostriatum; Neurons; Neuroprotective Agents; Neurotoxins; Parkinsonian Disorders; Selegiline; Substantia Nigra; Tyrosine 3-Monooxygenase; Zonisamide | 2010 |
Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dizocilpine Maleate; Dopamine; Dopamine Plasma Membrane Transport Proteins; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Extracellular Space; Glutamic Acid; Herbicides; Homovanillic Acid; Male; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Nerve Tissue Proteins; Neuroprotective Agents; Neurotoxins; NG-Nitroarginine Methyl Ester; Nitric Oxide; Paraquat; Parkinsonian Disorders; Quinoxalines; Rats; Rats, Wistar; Selegiline | 2003 |
D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Dopamine; Dose-Response Relationship, Drug; Hydroxyl Radical; Isomerism; Mice; Mice, Inbred BALB C; Monoamine Oxidase; Neostriatum; Neural Pathways; Neurons; Neuroprotective Agents; Neurotoxins; Parkinsonian Disorders; Selegiline; Substantia Nigra | 2003 |
Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Cell Death; Clorgyline; Disease Models, Animal; Ditiocarb; Dopamine; Down-Regulation; Drug Synergism; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Neostriatum; Neuroprotective Agents; Parkinsonian Disorders; Presynaptic Terminals; Selegiline; Substantia Nigra | 2003 |
Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Ditiocarb; Dopamine; Drug Synergism; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders; Reaction Time; Recovery of Function; Selegiline; Serotonin | 2003 |
sgk1, a member of an RNA cluster associated with cell death in a model of Parkinson's disease.
Topics: Age Factors; Animals; Antiparkinson Agents; Astrocytes; Blotting, Northern; Brain; Cell Death; Cluster Analysis; Disease Models, Animal; Drug Interactions; Food Deprivation; Gene Expression; Gene Expression Profiling; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Immediate-Early Proteins; In Situ Hybridization; Mice; Neurons; Nuclear Proteins; Parkinsonian Disorders; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selegiline; Time Factors; Tyrosine 3-Monooxygenase; Water Deprivation | 2005 |
L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Topics: Amphetamine; Animals; Catalase; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Electron Transport Complex I; Hydroxyl Radical; Male; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Selegiline; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase; Uncoupling Agents; Up-Regulation | 2006 |
A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Ethology; Gait Disorders, Neurologic; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Neural Pathways; Neuropharmacology; Parkinsonian Disorders; Predictive Value of Tests; Selegiline; Substantia Nigra; Tyrosine 3-Monooxygenase | 2007 |
Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Caudate Nucleus; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Drug Administration Schedule; Female; Injections, Subcutaneous; Male; Motor Activity; Motor Skills; Parkinsonian Disorders; Postural Balance; Premedication; Putamen; Radioligand Assay; Selegiline; Substantia Nigra | 2008 |
A possible association between exposure to n-hexane and parkinsonism.
Topics: Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Electromyography; Evoked Potentials, Auditory, Brain Stem; Evoked Potentials, Somatosensory; Hexanes; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Occupational Diseases; Parkinsonian Disorders; Selegiline; Solvents | 2000 |
CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Brain; Cell Culture Techniques; Cell Death; Disease Models, Animal; Dopamine; Female; Liver; Mesencephalon; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Oxepins; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Selegiline; Substantia Nigra; Tritium; Tyrosine 3-Monooxygenase | 2000 |
The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats.
Topics: Adrenergic Agents; Animals; Clorgyline; Corpus Striatum; Dopamine Agents; Dopamine Uptake Inhibitors; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidopamine; Parkinsonian Disorders; Piperazines; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra | 2000 |
Neuroprotective aspects of a novel MAO-B inhibitor PF9601N.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Indoles; Male; Methylamines; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinsonian Disorders; Selegiline | 2000 |
Selective inhibition of MAO-B through chronic low-dose (R)-deprenyl treatment in C57BL/6 mice has no effect on basal neostriatal dopamine levels.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinsonian Disorders; Selegiline | 2001 |
Rescue of dying neurons by (R)-deprenyl in the MPTP-mouse model of Parkinson's disease does not include restoration of neostriatal dopamine.
Topics: Animals; Antiparkinson Agents; Cell Death; Disease Models, Animal; Dopamine; Male; Mice; Mice, Inbred C57BL; Neostriatum; Neurons; Parkinsonian Disorders; Selegiline | 2001 |
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Callithrix; Disease Models, Animal; Dopamine; Dopamine Agents; Female; Immunohistochemistry; Indans; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Neostriatum; Neurons; Norepinephrine; Parkinsonian Disorders; Selegiline; Serotonin; Substantia Nigra | 2001 |